Showing 2451-2460 of 2527 results for "".
- Chinese Regulators Clear Takeda’s $62-Billion Takeover of Shirehttps://modernod.com/news/chinese-regulators-clear-takedas-62-billion-takeover-of-shire/2479882/Takeda said that China’s State Administration for Market Regulation has granted unconditional approval of its proposed $62-billion purchase of Shire. The Japanese drugmaker expects to complete the transaction in the first half of next year. China’s regulatory clearance “
- Oxurion NV Announces New NYSE Euronext Brussels Stock Ticker “OXUR” and Launch of New Websitehttps://modernod.com/news/oxurion-nv-announces-new-nyse-euronext-brussels-stock-ticker-oxur-and-launch-of-new-website/2479904/Oxurion NV announced the start of today’s trading under “OXUR” on NYSE Euronext Brussels. Effective today, the launch of a new ticker and website (
- Innovative “Pay It Forward” Training Program for Specialty Eye Surgeonshttps://modernod.com/news/innovative-pay-it-forward-training-program-for-specialty-eye-surgeons/2479905/The Refractive Surgery Alliance (RSA) announced the creation of a new and innovative training program for vision correction surgeons. The RSA program structure is unique and recognizes the expanding and rapidly evolving field refractive surgery. Instead of training surgeons under a single
- Commentary: Endothelial Cell Density After Iris-Fixated Phakic IOLhttps://modernod.com/news/endothelial-cell-density-after-iris-fixated-phakic-iol/2479908/There are three main types of phakic intraocular lenses (pIOL): those secured in the anterior chamber angle, those secured to the iris, and those placed between the crystalline lens and the iris. The latter two types are approved by the US Food and Drug Administration for use in the United States
- Devices to Expand Role of Surgery in Glaucoma Treatmenthttps://modernod.com/news/devices-to-expand-role-of-surgery-in-glaucoma-treatment/2479914/The glaucoma surgical device market is expected to grow at a rate of nearly 23 percent over the next 5 years, according to a Market Scope report. The market is expected to grow to nearly $1.7 billion by 2023, up from a small base of just under $634 million in 2018. Minimally invasive glauc
- ProtoKinetix Enters into 3rd Phase of Retinal Cell Replacement Therapy Testing at UBChttps://modernod.com/news/protokinetix-enters-into-3rd-phase-of-retinal-cell-replacement-therapy-testing-at-ubc/2479918/ProtoKinetix has entered into the 3rd phase of testing in retinal cell replacement therapy at the University of British Columbia. Due to the positive results from the first two phases of testing where the AAGP-treated cells showed a dramatic increase in survivability versus untreated cells over a
- Scientific Data for Novel Adeno-Associated Virus Gene Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa Publishedhttps://modernod.com/news/scientific-data-for-novel-adeno-associated-virus-gene-therapy-in-rhodopsin-mediated-autosomal-dominant-retinitis-pigmentosa-published/2479920/Ophthotech announced that scientists at the University of Pennsylvania (Penn) and University of Florida published proof-of-concept study results on an adeno-associated virus (AAV) gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-a
- Joseph Gordon Named US President of Bausch + Lombhttps://modernod.com/news/joseph-gordon-named-us-president-of-bausch-lomb/2479922/Bausch + Lomb announced that Joseph Gordon has been named US president, Bausch + Lomb. In this role, Mr. Gordon will oversee the fully integrated U.S. eye care business, inclusive of all four business units – Vision Care, Consumer Health, Surgical, and Pharmaceuticals. He will report direct
- EyeGate Announces Enrollment of First Patient in PRK Pilot Studyhttps://modernod.com/news/eyegate-announces-enrollment-of-first-patient-in-prk-pilot-study/2479928/EyeGate Pharmaceuticals announced that the first patient has been enrolled in its pilot study evaluating the ability of EyeGate’s Ocular Bandage Gel (OBG) to accelerate re-epithelialization of large corneal epithelial defects in patients having undergone photorefractive keratectomy (PRK) surgery.
- Bascom Palmer Eye Institute Ranked Nation’s No. 1 in Ophthalmology for 17th Timehttps://modernod.com/news/bascom-palmer-eye-institute-ranked-nations-no-1-in-ophthalmology-for-17th-time/2479945/U.S News & World Report has once again ranked Bascom Palmer Eye Institute of the University of Miami Health System as the nation’s best in ophthalmology. Recognized as a global leader in vision research, medical education and patient care, Basco